partnering on small activating RNA (saRNA) therapies to treat neurological diseases. saRNA is an entirely new class of drugs. They are small oligonucleotides, similar to siRNAs. This technology is MiNA’s focus, based on inventions from the company’s founder Pål Saetrom, which were assigned to MiNA by the Norwegian University of Science and Technology. The company has also in-licensed fundamental patents from UT Southwestern Medical Center that covers RNA activation therapeutics.
MiNA will leverage its saRNA platform to identify possible treatments to restore normal cell function in neurological diseases. Servier will handle preclinical and clinical development of potential candidates. Servier also will have the option for commercialization of any products coming out of the partnership.
Servier and MiNA Therapeutics Enter Collaboration in Neurological Diseases
MiNA eligible for up to 220 M€ in upfront, development and commercial milestone payments for first target.
Servier, a global and independent pharmaceutical Group, and MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today a research partnership to identify and develop small activating RNA (saRNA) therapies for the treatment of neurological disorders.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210121005329/en/
As part of the collaboration, MiNA Therapeutics will use its saRNA platform to identify new potential treatments to restore normal cell function in neurological disorders. Servier will be responsible for preclinical and clinical development of lead candidates and will have the rights for the commercialization of any products resulting from the collaboration. Under the terms of the agreement, MiNA Therapeutics